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a  b  s  t  r  a  c  t
Primary  malignant  ﬁbrous  histiocytoma  (MFH)  mainly  occurs  in  the  extremities,  trunk  and  retroperi-
toneum.  However,  MFH  of  the  mesentery  is  very  rare,  and locally  recurred  MFH is  even rarer.  MFH  is
severely malignant  and  invasive  regionally.  The  neoplasm  can  spread  quickly.  This  report  is about  a  case
of a recurred  MFH  in the mesentery,  which  locally  recurred  within  3 years  from  the  original  operation.
The  patient  (female,  age  71)  underwent  a resection  of  the  small  bowl  and  mesentery  of the  recurrenteywords:
alignant ﬁbrous histiocytoma
esentery
ecurrence
urgical treatment
rognosis
MFH  with  negative  resection  margins.  In the  24  months  that  followed,  there  has  not  been  any  evidence
of  recurrence  or  other  metastasis  in  the  patient.  Although  the prognosis  of  recurred  MFH  in mesentery
was  poor,  a  clear  resection  might  provide  a good  opportunity  for long-term  survival,  suggesting  that
surgery  might  be an effective  treatment.  This is the  ﬁrst report  on the  surgical  treatment  of  recurrent
MFH  of the  mesentery.
©  2016  The  Authors.  Published  by Elsevier  Ltd  on  behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Malignant ﬁbrous histiocytoma (MFH) is one of the most com-
on  sarcomas in the middle and late adulthood. It usually occurs in
he extremities, presenting as a painless mass and less commonly
n the mesentery, associated with weight loss and increased intra-
bdominal pressure [1]. The prognosis for MFH  is poor because of
ts strong chances of regional invasiveness and distant metastasis.
e report a rare case of recurrent MFH  that originated from the
leum mesentery.
. Presentation of case
A 69-year-old woman was admitted to our hospital because
f abdominal pain and a periumbilical palpable intra-abdominal
ass for 20 days. Physical examination revealed a huge, well cir-
umscribed, ﬁrm palpable mass in the left periumbilical area of the
bdomen. The vital signs of patient were stable. Carcinoembryonic
ntigen(CEA) and carbohydrate antigen 19-9(CA19-9) were within
ormal limits. Computed tomography (CT) of the abdomen and
elvis showed a large solid mass (long diameter: approximately
2 cm)  with well-deﬁned borders in the small bowel mesentery.
Fig. 1).
The patient underwent complete mass excision with free tumor
argin. There was no distant metastasis and peritoneal seeding.
he gross specimen was a well-encapsulated mass, measuring
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ospital, 17-1 Hyoja 3Dong, Chuncheon-Si, Kangwong-Do 24289, South Korea.
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ttp://dx.doi.org/10.1016/j.ijscr.2016.06.025
210-2612/© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
10 × 9.5 × 7.5 cm and weighing 488 gm. No necrotic area was
present. (Fig. 2) Microscopically, the tumor showed a whorled pat-
tern, long or short fascicles and high cellularity. (A) (H&E, ×100).
High power view of tumor cells showed marked pleomorphism
with bizarre nuclei. (B) (H&E, ×400) (Fig. 3A, B) In the immuno-
histochemical studies, the tumor cells were CD34(−), CD68(focal
+), Smooth Muscle Actin (SMA) (−), and Myogenin (−). (×100)
(Fig. 4A–D) The ﬁnal histopathologic diagnosis was malignant
ﬁbrous histiocytoma (or pleomorphic sarcoma) that originated
from the small bowel mesentery.
The patient refused further adjuvant chemotherapy and radio-
therapy. She underwent an abdominal CT every three months. After
3 years, the abdominal CT scan showed a 2 cm enhancing mass with
a partially indistinct margin in the mesentery of previous excision
site. A PET CT scan showed hypermetabolism in the soft tissue inﬁl-
tration of the mesentery. (Fig. 5A–B) Laboratory ﬁndings showed
within normal limit. At laparotomy, a 2 × 2 cm measured mass was
seen in the ileum mesentery, and a partial resection of the ileum
with mesentery was  performed. The pathologic diagnosis was con-
sidered recurrent MFH  of the small bowel mesentery. The patient
received chemotherapy with adriamycin, ifosfamide and mesna.
There was no evidence of local recurrence or distant metastasis at
24 months after the repeated surgery.
3. DiscussionO’Brien and Stout ﬁrst described Malignant ﬁbrous histiocytoma
(MFH) in 1964 [2]. MFH  is the most common soft tissue sarcoma
of people aged 60–70 years. It usually occurs in the extremities,
trunk, and retroperitoneum [3]. Primary MFH  of the mesentery is
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Abdominal CT shows a large solid mass with well-deﬁned borders in the small bowel mesentery.
Fig. 2. The Gross specimen was  a well-encapsulated mass, measuring 10 × 9.5 × 7.5 cm and weighing 488 gm.
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Mig. 3. Microscopically, the tumor showed a whorled pattern, long or short fascicle
leomorphism with bizarre nuclei. (B) (H&E, ×400).ery rare, and there is still an incomplete understanding of the
linicopathology of primary mesenteric MFH.
The clinical symptoms of primary intra-abdominal or intestinal
FH  are usually not speciﬁed. They appear comparatively late, and high cellularity. (A) (H&E, ×100). High power view of tumor cells showed markedabdominal pain, dyspepsia, and a palpable abdominal mass are gen-
eral symptoms. Due to the lack of a speciﬁc clinical presentation or
images or tumor markers, it is difﬁcult to make the preoperative
differential diagnosis of mesenteric MFH.
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Fig. 4. A-4AD In the immunohistochemical studies, the tumor cells were CD34(−), CD68(+), Smooth Muscle Actin (SMA)(−), and Myogenin (−). (×100).
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Mig. 5. Abdominal CT shows an ill-deﬁnedmass with perilesional inﬁltration in t
esentery.(B).
The CT ﬁndings of the MFH  in the mesentery were an irreg-
larly margined, heterogeneously enhancing mass with irregular
eritumoral strands in the mesentery [4]. MFH  is microscopically
haracterized by areas of spindle cells arranged in a storiform pat-
ern and pleomorphic areas with haphazardly arranged sheets of
broblasts and histiocytes. The diagnosis of MFH  depends on an
ccurate differential diagnosis of other sarcomas. The differential
iagnosis includes gastrointestinal stromal tumor, ﬁbrosarcoma,
eiomyosarcoma, and myxoid sarcoma. MFH  frequently expresses
imentin, actin, alpha 1-antichymotrypsin, CD 68, desmin and CD
4, which were useful to a differential diagnosis [5]. The CD 68 was
ositive in the present case.
Surgical resection with negative resection margins is the stan-
ard treatment for primary MFH  of the mesentery. The efﬁcacy
f radiotherapy is well established in the adjuvant treatment of
FH of the extremities. However, in the case of mesenteric MFH,sentery. (A) PET CT shows hypermetabolism in the soft tissue inﬁltration of the
the efﬁcacy of radiotherapy is uncertain. A group of investigators
reported that postoperative chemotherapy increased the survival
rate, but another group of investigators has reported that postoper-
ative chemotherapy did not achieve curative results. Doxorubicin
is the ﬁrst treatment option for unresectable or partially resected
soft tissue sarcoma, but palliative or intensiﬁed chemotherapy to
MFH  have failed to beneﬁt survival [6].
The prognosis for MFH  is poor. The 2-year survival rate is 60%,
and the rate of metastasis is 42% [3]. Resection with clear resection
margins was  associated with improved disease speciﬁc survival
[6]. Prognosis depends on the grade, the depth, the size and the
subtype of the tumor, metastasis and the age of a patient. Tumor
site (extremity vs non-extremity), location (proximal vs distal),
size (≤5 cm vs >5 cm), and histology (myxoid vs non-myxoid) are
not signiﬁcant determinants of ﬁnal outcomes [7]. For metastatic
relapse, the major determinants were histology (myxoid vs non-
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yxoid) and tumor size. Myxoid tumors have a low metastatic
ropensity (13% 10-year metastatic rate) compared to non-myxoid
umors (40% 10-year metastatic rate) [3]. Although the progno-
is of non-extremity recurrent MFH  is poor, there are still some
ases with good prognosis after repeated surgery of recurrent MFH.
cGrady et al. reported that a case was alive 9 years after resec-
ion of the recurred primary hepatic MFH  [8]. Yutaka Okita et al.
eported that a case was  alive 6 years after resection of the recurred
eft atrium MFH  [9]. Kitazono I and Saigenji H reported that a
ase was alive 57 months after resection of the recurred chest
all MFH  [10]. In our case, the patient was doing well without
pparent recurrence 24 months after repeat surgery and is still
live at 57 months after initial surgery. To our knowledge, there
ere some case reports on mesentery MFH, but there was  no case
eport on surgical treatment of recurred mesentery MFH  in the
nglish-language literature [5,7]. This is the ﬁrst report on surgical
reatment of recurrent MFH  of the mesentery.
. Conclusion
MFH  of the mesentery is a highly malignant tumor with early
ecurrence and metastatic spread. The most reliable treatment is
omplete surgical excision of the tumor with free margins. Due
o the high rate of recurrence, continuous clinical observation is
trongly recommended. If local recurrence of mesenteric MFH  is
etected, an aggressive surgical treatment is the best cure to pro-
ong the patient’s survival.
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